Aspire Biopharma (ASBP) Income Statement (2021 - 2026)
Income Statement report data from Mar 31, 2021 to Mar 31, 2026 for Aspire Biopharma (ASBP).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | ||||||||||||||||||||
Total Revenue | 30K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost Of Revenue | 20K (+100.00%) | 10K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Costof Goods And Services Sold | 20K (+100.00%) | 10K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 10K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses | ||||||||||||||||||||
Research And Development | 300K (+200.00%) | 100K (-52.38%) | 210K (-40.00%) | 350K (+34.62%) | 260K (+116.67%) | 120K (+1100.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K | - | - | - | - | - | - | - | - |
Selling General And Administrative | 1.02M (-38.18%) | 1.65M (+223.53%) | 510K (+27.50%) | 400K (-97.35%) | 15M (+468.68%) | 2.65M (+320.63%) | 630K (+26.00%) | 500K (-80.16%) | 2.52M (+530.00%) | 400K (+53.85%) | 260K (-10.34%) | 290K (-9.38%) | 320K (+3.23%) | 310K (+19.23%) | 260K (-13.33%) | 300K | - | 20K | - | 10K |
Operating Expenses | 1.65M (-10.81%) | 1.85M (+60.87%) | 1.15M (+43.75%) | 800K (-94.86%) | 16M (+517.46%) | 2.52M (+1045.45%) | 220K (-56.00%) | 500K (-80.16%) | 2.52M (+530.00%) | 400K (+25.00%) | 320K (+10.34%) | 290K (-9.38%) | 320K (+3.23%) | 310K (+19.23%) | 260K (-13.33%) | 300K | - | 20K | - | 10K |
Depreciation And Amortization | 1.58M (-73.67%) | 6.00M (+197.03%) | 2.02M | - | -2.63M | 2.44M | - | 110K (-31.25%) | 160K (-60.00%) | 400K (+25.00%) | 320K (+10.34%) | 290K (-9.38%) | 320K | - | 260K (-13.33%) | 300K | - | 20K | - | 10K |
Operating Income | ||||||||||||||||||||
Operating Income | -1.65M (-10.81%) | -1.85M (+60.87%) | -1.15M (+43.75%) | -800.00K (-94.86%) | -15.56M (+517.46%) | -2.52M (+1045.45%) | -220.00K (-56.00%) | -500.00K (-80.16%) | -2.52M (+530.00%) | -400.00K (+25.00%) | -320.00K (+10.34%) | -290.00K (-9.38%) | -320.00K (+3.23%) | -310.00K (+24.00%) | -250.00K (-16.67%) | -300.00K | - | -20.00K | - | -10.00K |
Ebit | -1.65M (-10.81%) | -1.85M (+400.00%) | -370.00K (-53.75%) | -800.00K (-92.01%) | -10.01M (-9.66%) | -11.08M (+4516.67%) | -240.00K (-52.00%) | -500.00K (+212.50%) | -160.00K (-70.37%) | -540.00K (+68.75%) | -320.00K (+10.34%) | -290.00K | 2.87M | - | -250.00K (-16.67%) | -300.00K | - | -30.00K | - | -20.00K |
EBITDA | -60.00K | 4.15M (+151.52%) | 1.65M | -1.45M (-90.73%) | -15.65M (+41.25%) | -11.08M (+1658.73%) | -630.00K (+61.54%) | -390.00K (-82.89%) | -2.28M (+1528.57%) | -140.00K | - | - | 3.20M (+43.50%) | 2.23M | - | - | - | -20.00K | - | -10.00K |
Other Income / Expenses | ||||||||||||||||||||
Interest Income | 10K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense | 1.60M (-74.32%) | 6.23M (+320.95%) | 1.48M (+179.25%) | 530K (+82.76%) | 290K (-67.42%) | 890K (+8800.00%) | 10K (-95.24%) | 210K (+16.67%) | 180K (+1700.00%) | 10K | - | - | - | - | - | - | - | - | - | - |
Net Interest Income | -1.59M (-74.48%) | -6.23M (+320.95%) | -1.48M (+179.25%) | -530.00K (+82.76%) | -290.00K (-14.71%) | -340.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | ||||||||||||||||||||
Income Before Tax | -3.22M (-31.63%) | -4.71M (+154.59%) | -1.85M (-6.57%) | -1.98M (-87.58%) | -15.94M (+33.17%) | -11.97M (+2116.67%) | -540.00K (-10.00%) | -600.00K (-75.71%) | -2.47M (+1546.67%) | -150.00K (+114.29%) | -70.00K | 1.81M (-36.93%) | 2.87M (+28.70%) | 2.23M (+106.48%) | 1.08M (+800.00%) | 120K | - | -20.00K | - | -10.00K |
Net Income From Continuing Operations | -3.22M (-31.63%) | -4.71M (+154.59%) | -1.85M (-6.57%) | -1.98M (-87.58%) | -15.94M (+33.17%) | -11.97M (+4887.50%) | -240.00K (+140.00%) | -100.00K (-56.52%) | -230.00K (+187.50%) | -80.00K (+14.29%) | -70.00K (-22.22%) | -90.00K | - | - | - | - | - | - | - | - |
Net Income | -3.22M (-31.63%) | -4.71M (+154.59%) | -1.85M (-6.57%) | -1.98M (-87.58%) | -15.94M (+33.17%) | -11.97M (+2116.67%) | -540.00K (-10.00%) | -600.00K (-75.71%) | -2.47M (+1546.67%) | -150.00K (+114.29%) | -70.00K | 1.81M (-36.93%) | 2.87M (+28.70%) | 2.23M (+106.48%) | 1.08M (+800.00%) | 120K | - | -20.00K | - | -10.00K |